Skip to main content
Article
Efficacy of Antiseptic Mouthrinses Against SARS-CoV-2: A Prospective Randomized Placebo-Controlled Pilot Study.
American Journal of Otolaringology (2022)
  • Alessandro Villa
  • P. J. Fantozzi
  • E. Pampena
  • A. Pierangeli
  • G. Oliveto
  • L. Sorrentino
  • D. Di Vanna
  • R. Pampena
  • A. Lizzaro
  • E. Gentillini
  • C. M. Mastroianni
  • G. D'Ettore
  • A. Polimeni
  • U. Romeo
Abstract
Objectives: Coronavirus-disease-19 (COVID-19) continues to affect millions of individuals worldwide. Antiviral activity of mouthrinses remains an important research area as the oral cavity is a site of SARS-CoV-2 initial replication. The aim of this study was to assess the effectiveness of three different mouthrinses in reducing the oral/oropharyngeal SARS-CoV-2 viral load.
Methods: Adult patients, hospitalized with confirmed COVID-19 were recruited for the study. Oral/oropharyngeal baseline SARS-CoV-2 samples were collected and analyzed by Real-Time-PCR. Subsequently, patients were instructed to rinse with 1 % hydrogen peroxide (H2O2), 0.12 % chlorhexidine (CHX), 1 % povidone‑iodine (PVP-I) or Sodium Chloride 0.9 % (placebo). Viral loads were measured right after (T1), and at 45 min (T2) from the rinse.
Results: In the PVP-I 1 % group, 5/8 (62.5 %) patients at T1, and 3/8 (37.5 %) patients at T2, SARS-CoV-2 was not detectable in the swab specimens. In the H2O2 1 % group, 2/11 (18.2 %) patients at T1, and 2/11 (18.2 %) other patients at T2 showed no SARS-CoV-2 loads. One (12.5 %) patient in the CHX 0.12 % group showed SARS-CoV-2 negativity at T2. One (9.1 %) patient at T1, and another (9.1 %) patient at T2 showed no SARS-CoV-2 loads in the placebo group.
Conclusions: Oral SARS-CoV-2 loads were reduced at T1 in the PVP-I 1 % and H2O2 1 % groups.
Clinical relevance: PVP-I 1 % was the most effective rinse especially in patients with low viral copy numbers at baseline.
Keywords: COVID-19; Chlorhexidine; Disinfection; Mouth; Oral cavity; Oral diseases; Oral medicine; Oral rinses; Povidone‑iodine; Public health; Saliva.
Keywords
  • Efficacy,
  • Antiseptic,
  • Mouthrinses,
  • SARS-Cov-2,
  • Randomized,
  • Controlled Study
Publication Date
July 28, 2022
DOI
10.1016/j.amjoto.2022.103549
Citation Information
Alessandro Villa, P. J. Fantozzi, E. Pampena, A. Pierangeli, et al.. "Efficacy of Antiseptic Mouthrinses Against SARS-CoV-2: A Prospective Randomized Placebo-Controlled Pilot Study." American Journal of Otolaringology Vol. 43 Iss. 6 (2022) p. 103549 ISSN: 0196-0709
Available at: http://works.bepress.com/alessandro-villa/3/